EGFR and neoplasm: This study reported that blockage of EGFR with cetuximab in AsPC-1 xenograft tumors decreased the tumor uptake of the radiotracer up to three folds while blocking the HER3 receptors with DL3.6b did not alter the radiotracer uptake.